Pharmalot (Free subscription) | 29/09/2008
How’s this for chutzpah? Along with Biopure and two other former execs, Howard Richman was accused in 2005 by the Securities and Exchange Commission of misleading investors about the progress of the Hemopure artificial blood product, which the FDA had so far refused to approve over safety concerns (see lawsuit). To escape the SEC litigation and [...]
www.BackgroundNow.com Weblog (Free subscription) | 28/09/2008
Howard Richman, the former head of regulatory affairs of Biopure Corporation, was indicted by a grand jury convened by the United States Attorney for the District of Massachusetts for, among other... This is a mere summary. Go to http://www.backgroundnow.com/blog for the real deal.
Boston Globe (Free subscription) | 25/09/2008
A former executive of a Cambridge-based biotech company lied to a federal judge when he said he was gravely ill from colon cancer - an attempt to dodge a costly federal lawsuit over problems stemming from an experimental synthetic blood product, federal officials said yesterday.
Boston Globe (Free subscription) | 25/09/2008
A former executive of Biopure Corp. has been charged with falsely telling a federal judge he had terminal cancer to dodge a Securities and Exchange Commission complaint.
PR News Wire (Free subscription) | 21/08/2008
CAMBRIDGE, Mass., Aug. 21 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: ) today announced its financial results for the third fiscal quarter ended July 31, 2008. For the quarter, the company reported a net loss of $4.6 million, or $0.13 per common share, compared with a net loss of $6.4 million, or $0.41 per common share, for the corresponding period in 2007. Class A common shares outstanding...
Fiercebiotech (Free subscription) | 08/08/2008
Howard Richman, the former chief of regulatory affairs for Biopure, agreed to pay a $150,000 fine to settle federal charges that he had helped mislead investors in the company over the prospects of the blood substitute Hemopure at the FDA. Richman was barred from serving as an officer or director of a public company but did not admit or deny any of the allegations in the settlement. Three other company...
PharmaGossip (Free subscription) | 08/08/2008
Former Biopure Corp. head of regulatory affairs Howard Richman agreed to pay a $150,000 penalty to settle allegations that he misled investors about the Cambridge biotechnology company's efforts to obtain approval for its synthetic blood product, Hemopure. Richman will also be permanently barred from serving as an officer or director of any public company under the final judgment entered in US District...
Law Blog - WSJ.com (Free subscription) | 07/08/2008
A former Biopure executive agreed to pay a $150,000 civil penalty to settle allegations that he misled investors about the biotech company's prospects for obtaining regulatory approval for its synthetic blood product, Hemopure.
The Boston Business Journal (Free subscription) | 07/08/2008
Former Biopure Corp. executive Howard Richman will lose his ability to run a public company as a part of a settlement with the Securities and Exchange Commission regarding misleading statements he allegedly made regarding the company’s signature product. Richman, 56, is permanently prevented from violating federal antitrust and securities laws and barred from serving as an officer or director of any...
Fiercebiotech (Free subscription) | 08/07/2008
Just weeks after laying off more than half of its staff, the struggling Cambridge, MA-based Biopure said that it's been in talks with the FDA on identifying an acceptable population of patients for a new trial involving the controversial blood substitute Hemopure . Biopure wants to mount a trial of AML patients who refuse transfusion with blood components. "Currently, AML patients who do not accept...
PR News Wire (Free subscription) | 07/07/2008
CAMBRIDGE, Mass., July 7 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: ) announced today that it has had discussions with the Food and Drug Administration (FDA) on identifying an acceptable patient population for a new clinical trial of Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201. Biopure has proposed to study use of Hemopure in patients suffering from Acute Myelogenous Leukemia...
Red Orbit (Free subscription) | 03/07/2008
CAMBRIDGE, Mass., July 2 /PRNewswire-FirstCall/ -- Biopure Corporation announced today that it has signed an agreement with purchasers for a private placement of its common stock and warrants for up to $2.3 million in tranches, assuming no exercise of the warrants.
PR News Wire (Free subscription) | 02/07/2008
CAMBRIDGE, Mass., July 2 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: ) announced today that it has signed an agreement with purchasers for a private placement of its common stock and warrants for up to $2.3 million in tranches, assuming no exercise of the warrants. The company intends to use the net proceeds for working capital and general corporate purposes. The first closing occurred on...
Rock The Truth (Free subscription) | 21/06/2008
And, of course, it is a BRIEF! After a WEEK of CROWING about the Guv's biotech success! Fuck you, Globe!!! " Biopure lays off 50, needs cash to stay open past fall "Biopure Corp., a Cambridge biotech company, said it laid off 50 employees, or about 60 percent of its staff, this week to slash expenses . But spokeswoman Tiana Gorham confirmed that even with the cuts, Biopure likely only has enough cash...
PR News Wire (Free subscription) | 12/06/2008
CAMBRIDGE, Mass., June 12 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: ) announced today that The NASDAQ Stock Market has granted the Company an additional 180 days, or until December 8, 2008, to regain compliance with Marketplace Rule 4310(c)(4) requiring a minimum bid price of $1.00 for continued listing. Currently, the Company meets all other required inclusion criteria for the NASDAQ...
